Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers

27 Oct 2017

Abstract excerpt

Clear cell carcinoma and endometrioid adenocarcinoma are histologic subtypes of ovarian and uterine cancer that demonstrate unique clinical behavior but share common underlying genomic aberrations and oncogenic pathways. ARID1A mutations are more frequently identified in these tumors, in comparison to other gynecologic histologies, and loss of ARID1A tumor suppressor function is thought to be an essential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29093822
DOI: 10.1186/s40661-017-0052-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancersPMID 29093822Read ↗

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.Semantic proximity Read ↗

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategiesSemantic proximity Read ↗

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.Semantic proximity Read ↗

ARID1A gene mutation in ovarian and endometrial cancers (Review).Semantic proximity Read ↗

Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.Semantic proximity Read ↗

Targeting DNA Damage Response Pathway in Ovarian Clear Cell CarcinomaSemantic proximity Read ↗

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.Semantic proximity Read ↗

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.Semantic proximity Read ↗

ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.